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Background: Increased bone resorption is a well-described consequence of primary hyperparathyroidism (PHPT). In South
Africa, little is known about the impact of PHPT on skeletal health.
Objective: To determine the prevalence of decreased bone mineral density (BMD), vertebral fractures and osteitis fibrosa
cystica in patients with PHPT who underwent parathyroidectomy.
Methods: Retrospective study of patients who underwent parathyroidectomy for PHPT at Tygerberg Hospital in Cape Town,
from January 2010 to December 2019. Clinical, biochemical and BMD parameters are described.
Results: Final analysis included 56 patients (median age 63.5 years; 80.4% female). Initial calcium, parathyroid hormone (PTH)
and 25-hydroxyvitamin D (25[OH]D) levels were 2.93 mmol/l, 19.4 pmol/l and 34.0 nmol/l, respectively. Of the total cohort,
71.4% had decreased BMD. The prevalence of osteoporosis and osteopenia in postmenopausal women and men ≥ 50 years
was 50.0% and 39.1% respectively; low bone mass for age in premenopausal women and men < 50 years was 20.0%.
Vertebral fractures were seen in 21.2% of patients on radiography. Osteitis fibrosa cystica was present in five patients
(9.6%). PTH levels were significantly elevated in patients with osteoporosis compared with those with normal BMD (36.4 vs.
16.1 pmol/l; p = 0.02).
Conclusion: Two-thirds of patients who underwent parathyroidectomy for PHPT had decreased BMD, with osteoporosis
present in 50% of postmenopausal women and older men. One in five had vertebral fractures. These findings underscore
the importance of skeletal assessment in the management of PHPT.
Keywords: calcium, bone mineral density, fracture, osteoporosis, osteitis fibrosa cystica, parathyroid hormone, primary
hyperparathyroidism
Introduction
Primary hyperparathyroidism (PHPT) is the most common cause
of chronic hypercalcaemia in the outpatient population world-
wide.1,2 It is defined as a raised serum calcium level with a sim-
ultaneously elevated or inappropriately unsuppressed
parathyroid hormone (PTH) level. PHPT affects bone mineral
metabolism and renal calcium handling early in the course of
the disease.3 The adverse skeletal effects can be independent
of symptoms,4 thus the quantification of bone involvement is
of paramount importance.5 The chronic exposure of the skel-
eton to excess parathyroid hormone in PHPT is characterised
by high bone turnover4 with osteoclastic activity and resultant
bone resorption predominating over bone formation.6 This
leads to skeletal pathology ranging from a subclinical decrease
in bone mineral density (BMD) to osteoporosis with fragility
fractures and osteitis fibrosa cystica (OFC).6,7 Osteoporosis, irre-
spective of evidence of fragility, is considered to be an indi-
cation for surgical parathyroidectomy.5
In well-resourced healthcare environments, the clinical presen-
tation of PHPT has shifted from that of severe skeletal and renal
pathology to one of mild or asymptomatic disease,8 attributable
to the increased availability of automated multichannel serum
biochemical testing.8,9 Earlier diagnosis has been slower to
occur in the developing world,10,11 with the majority of patients
still presenting with symptomatic disease.7,10,12 In resource-
limited environments, such as the public healthcare sector in
South Africa, hypercalcaemia is frequently occult in asympto-
matic patients. However, even in asymptomatic PHPT, insidious
decline in skeletal health can occur.13,14 Compromised skeletal
strength, as evidenced by decreased BMD and suboptimal
bone quality, is associated with increased fracture risk3,15 and
significant morbidity.16
Bone mineral density, a robust indicator of skeletal strength, is
measured by dual-energy X-ray absorptiometry (DXA). The
accelerated bone loss seen in PHPT is linked to the duration
and the severity of unopposed PTH excess.17 Accelerated loss
of BMD also occurs during female menopause and in normal
ageing, overlapping with the population that develops PHPT.
Primary hyperparathyroidism most often affects people older
than 50–65 years, with women affected twice more often
than men.18 Fracture risk, however, remains higher in PHPT
than matched controls,19,20 irrespective of BMD category,
†The last two authors contributed equally to the manuscript.
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suggestive of an adverse effect of continuous exposure of the
skeleton to excess PTH on non-BMD related bone quality.
Despite the protective effects of bisphosphonates and other
anti-resorptive agents on bone, the only definitive management
of PHPT is surgical removal of the autonomous parathyroid
gland(s). Correction of hypercalcemia, improvement in BMD
and fracture risk reduction is the norm after parathyroidect-
omy.17,21–24
Very little has been reported on PHPT and its impact on bone
health in sub-Saharan Africa. DXA is not readily available in
the public health sector, apart from specialist centres, and
national disease registries for endocrine disorders do not
exist. In this study, we aim to determine the prevalence of
osteoporosis, osteopenia and vertebral fractures (VF) in South
African patients who had surgery for PHPT.
Methods
Study cohort and data sources
The present study was a retrospective description of patients
who underwent parathyroidectomy for PHPT from January
2010 to December 2019 at Tygerberg Hospital (TH), Cape
Town, South Africa. Only patients with a confirmed diagnosis
of PHPT were selected for inclusion. Patients were excluded if
they did not have a DXA scan on record, or if their DXA scan
occurred more than three weeks after parathyroidectomy.
Data sources were the OpenText ECM (Enterprise Content Man-
agement) system (https://www.opentext.co.uk/products-and-
solutions/products/enterprise-content-management) for
storage and retrieval of patient clinical records, the National
Health Laboratory Services (NHLS) for chemical and anatomical
pathology results, and a picture-archiving and communication
system (PACS, Phillips, South Africa) for all radiological investi-
gations. Epidemiological information (age, ethnicity, sex, meno-
pausal status and comorbidities), symptoms of PHPT and
medication use (specifically corticosteroid use, bisphosphonate
administration and preoperative vitamin D supplementation)
were recorded.
Anthropometric data (weight and height) were sourced from
the DXA scan reports, performed by a single operator for the
study period. Body mass index (BMI) was calculated with the
formula BMI = weight(kg)/height(m)2. BMI was categorised
according to the World Health Organization (WHO) as under-
weight, normal, overweight and obese.25
Biochemistry
All laboratory analyses were performed on-site at TH NHLS, a
South African National Accreditation System (SANAS) accre-
dited medical laboratory service. Preoperative biochemistry
included serum total calcium, magnesium and phosphate
levels, intact PTH, urea and creatinine as well as serum alkaline
phosphatase (ALP) and 25-hydroxyvitamin D (25[OH]D) levels.
The highest pre-bisphosphonate (if given), preoperative
calcium, concurrent PTH and ALP were recorded as well as
the nadir vitamin D level prior to supplementation. Urine
calcium excretion was recorded where available. At TH NHLS
a Roche Cobas® analyser was used for the measurement of
serum total calcium (by spectrophotometric detection), as
well as intact PTH and 25(OH)D (both by electrochemilumines-
cence binding assay). Laboratory reference ranges were as
follows: total calcium 2.15–2.50 mmol/l, PTH 1.6–6.9 pmol/l
and ALP 42–98 U/l. 25(OH)D levels, expressed in nmol/l, are
defined as deficient (< 50 nmol/l), insufficient (52.5–
72.5 nmol/l) and sufficient (> 75 nmol/l).26
Skeletal assessment, categorisation of BMD and
fracture definition
DXA scan reports were reviewed for the presence of one or
more VFs by morphometric assessment. Bone mineral density
values (g/cm2), as well as T- and Z-scores, were recorded for
the spine, proximal femur (femoral neck and total hip region)
and the non-dominant, distal-third forearm. Thresholds for
diagnosis of a decreased BMD are defined as per the WHO.27
In postmenopausal women and men≥ 50 years, osteoporosis
is defined as a T-score <−2.5 and osteopenia as a T-score of
−1.0 to −2.5 at any measured site. In premenopausal women
and men under the age of 50 years, low bone mass for age is
defined as a Z-score of <−2.0. DXA studies, employing the
Hologic Discovery-W, S/N 70215 (software version 13.1;
Hologic Canada ULC, Misisissauga, ON, Canada), were all per-
formed in-house at the Division of Endocrinology at TH. All
the DXA scans were performed and reported by a single experi-
enced technician.
Plain-film radiographs were retrospectively evaluated by a
single specialist radiologist in the Department of Medical
Imaging at TH who reported on the presence of one or more
VFs as well as any other radiological features in keeping with
PHPT. A vertebral fracture was diagnosed if more than 20%
reduction in anterior, middle and/or posterior vertebral body
height was present.28 Fractures were regarded as fragility frac-
tures if they occurred in the presence of minimal trauma or
due to falling from standing height.29 The diagnosis of osteo-
porosis was based on WHO DXA BMD criteria and/or the pres-
ence of fragility fracture of the spine on conventional radiology.
Perioperative management
When considering the indication for surgery, participants were
coded as ‘symptomatic’ if review of medical records revealed
only symptoms attributable to PHPT without evidence of
target organ damage, or they were coded as having renal
and/or skeletal indications where these were present. In
addition, other surgical indications including ‘age younger
than 50 years’ and ‘calcium level over 0.25 mmol/l above the
upper limit of normal’ were recorded if present.5
Ethical considerations
The study was approved by the Human Research Ethics Com-
mittee, Faculty of Medicine and Health Sciences, Stellenbosch
University and Tygerberg Hospital (S20/01/007). Data collection
was performed by the principal investigator only, with all infor-
mation stored on a password-protected computer. Data were
de-identified prior to statistical analysis.
Statistical analysis
Data analyses were conducted using SPSS Statistics for
Windows, version 26 (IBM Corp, Armonk, NY, USA). Continuous
variables were summarised as median and interquartile range
(IQR) or mean and standard deviation as appropriate. Categori-
cal variables were summarised as counts and percentages. The
Spearman correlation coefficient was used to determine
whether there were significant associations between continu-
ous variables. Where appropriate, the Mann–Whitney U-test or
the Kruskal–Wallis test was used to assess differences in con-
tinuous variables between two or more independent groups.
Statistical significance was set at p < 0.05.
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Results
Patient demographics and indication for
parathyroidectomy
A total of 163 patients underwent parathyroidectomy during
the study period, of which 104 were confirmed to have PHPT.
Of the 104 patients with PHPT, 56 had DXA studies prior to
their surgery and were included in the final analysis. As
shown in Table 1, most patients (n = 46; 82.1%) were≥ 50
years old (median age 63.5 years [53;70]) and female (n = 45;
80.4%). Thirty-eight women were postmenopausal )38/45;
84%) and 2/11 men were below the age of 50 years. Most of
the patients were either overweight (n = 13; 23.2%) or obese
(n = 29; 51.8%). Ten patients (17.9%) were found to have a
normal BMI and four (7.1%) were underweight. Considering
modifiable risk factors for excessive bone loss, less than one-
third of the cohort (n = 15; 26.8%) had a condition other than
PHPT associated with decreased BMD. This included: active ciga-
rette smoking (n = 10; 17.9%), any corticosteroid use (n = 3;
5.4%) and concomitant rheumatological disease not managed
with corticosteroids (n = 2; 3.6%).
The indications for parathyroidectomy are listed in Table 1. The
majority of patients (n = 46, 82.1%) had two or more indications
for parathyroidectomy; 94.6% of participants (n = 53) had a
serum calcium levels in excess of 2.75 mmol/l. Of the patients
who qualified for parathyroid surgery, 41.1% (n = 23) had
osteoporosis.
Baseline biochemistry
Baseline biochemistry is given in Table 2. All but one patient had
elevated calcium levels (median: 2.93 mmol/l [2.81; 3.19]) and
the vast majority (n = 53; 94.6%) displayed a calcium concen-
tration of > 2.75 mmol/l. The single patient with normocalcae-
mia (calcium level 2.45 mmol/l) had a PTH of 12.9 pmol/l and
symptoms attributable to hypercalcaemia (normocalcaemic
hyperparathyroidism). Severe hypercalcaemia (> 3.50 mmol/l)
was seen in 14.3% of patients. Concomitant decreased phos-
phate concentrations (mean: 0.87 ± 0.24 mmol/l) were seen in
Table 1: Clinical characteristics and indications for surgery in patients
with PHPT (n = 56)
Clinical characteristics






< 50 years of age 2







Weight (kg) 77.4 ± 18.6
Height (m) 1.62 ± 0.09
BMI (kg/m2) 29.7 ± 7.3
Underweight (BMI < 18.5) 4 (7.1%)
Normal (BMI 18.5–24.9) 10 (17.9%)
Overweight (BMI 25–29.9) 13 (23.2%)
Obese (BMI > 30) 29 (51.8%)
Other comorbidities and risk factors for osteoporosis:
Hypertension 39 (69.6%)
Smoking, current 10 (17.9%)
Systemic corticosteroids, current 3 (5.4%)
Rheumatological disease (RA/SLE) 2 (3.6%)
Indications for parathyroidectomy:
Symptomatic, no target organ damage 12 (21.4%)
Age < 50 years 10 (17.9%)
Calcium > 2.75 mmol/l 53 (94.6%)
Osteoporosis 23 (41.1%)
Renal 17 (30.4%)





aMedian and interquartile range are indicated for non-normally distributed data.
bMean ± standard deviation shown for normally distributed data.
Categorical data are expressed as n (%).
Table 2. Baseline biochemistry of total sample (n = 56)
Biochemical parameter Total cohort
Total serum calcium* (normal range 2.15–
2.50 mmol/l)
2.93 (2.81; 3.19)
Ca 2.15–2.74 mmol/l 3 (5.4%)
Ca 2.75–2.99 mmol/l 30 (53.6%)
Ca 3.00–3.49 mmol/l 15 (26.8%)
Ca > 3.50 mmol/l 8 (14.3%)
Phosphate** (normal range 0.78–1.24 mmol/l) 0.87 ± 0.24
Phosphate < 0.78 mmol/l 20 (35.7%)
Magnesium** (normal range 0.63–1.05 mmol/l) 0.84 ± 0.17
Magnesium < 0.63 mmol/l 5 (8.9%)
PTH* (normal range 1.6–6.9 pmol/l) 19.4 (14.5; 42.3)
PTH > 6.9 pmol/l 54 (96.4%)
PTH within normal range 2 (3.6%)
PTH 5.1–6.9 pmol/l 1 (1.8%)
PTH < 5.0 pmol/l 1 (1.8%)
ALP* (normal range 42–98 U/l; n = 45) 88.0 (74.0;
122.5)
ALP elevated 21 (46.7%)
25(OH)D*a (nmol/l; n = 49) 34.0 (23.6; 48.0)
Deficient (< 50.0 nmol/l) 39 (79.6%)
Insufficient (52.5–72.5 nmol/l) 8 (16.3%)
Sufficient (> 72.5 nmol/l) 2 (4.1%)
Creatinine* (F 49–90 umol/l, M 64–104 umol/l) 87.5 (69.3;
121.8)
Creatinine elevated from baseline (n = 17) 24 (42.9%)
Urine calcium* (normal range 2.5–7.50 mmol/l; n =
27)
2.07 (1.14; 3.25)
24-hour urine calcium* 5.00 (1.80; 7.20)
24-hour urine calcium 7.51–9.99 mmol/24 hour 3 (11.1%)
24-hour urine calcium > 10 mmol/24 hourb 3 (11.1%)
Cohort size is n = 56 unless otherwise stated. Data expressed as n (%) or as indi-
cated by asterisk, as median (IQR)* or mean (± SD)** as appropriate. a Rec-
ommended classification of 25OHD values as either deficient, insufficient or
sufficient according to the Endocrine Society clinical practice guideline26.
b24-hour urine calcium > 10 mmol/l/24 hours indication for surgery per se.
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20 patients (35.7%). Parathyroid hormone levels exceeded the
reference interval in all but two patients (54; 96.4%). These
two patients had PTH values in the upper half of the normal
range (PTH 4.1 and 5.9 pmol/l; reference interval 1.6–
6.9 pmol/l), deemed inappropriate given the elevated calcium
level.
Increased serum alkaline phosphatase (ALP) without coexistent
elevations in gamma-glutamyl transferase (GGT), thus pre-
sumed to be mostly from skeletal origin, was present in 21
patients (46.7%). Most patients (n = 39/49; 79.6%) were found
to have deficient (< 50 nmol/l) 25(OH)D levels, with only two
(4.1%) displaying 25(OH)D levels within the ‘sufficient’ range.
Urine calcium excretion was quantified by 24-hour urine collec-
tion in 27 patients; three of these patients were found to have a
level greater than 10 mmol/24 hours.
Serum calcium levels were positively associated with both PTH
(r = 0.46; p < 0.01) and ALP levels (r = 0.34; p = 0.02). In addition,
ALP levels were positively associated with PTH levels (r = 0.49;
p < 0.01). Inverse associations were evident between 25(OH)D
levels and (i) PTH levels (r =−0.43; p < 0.01) and (ii) calcium
levels (r =−0.33, p = 0.02). The PTH and 25(OH)D levels were
similar across the BMI range.
Bone mineral density and the prevalence of
osteopenia, osteoporosis and vertebral fractures
BMD at the lumbar spine (LS), femoral neck (FN), total hip region
(THR) and distal-third forearmwere available for 56, 48, 55 and 18
patients, respectively. Conventional radiographs were available
for 52 of the 56 patients within six months of their DXA scan.
In the total study cohort, decreased BMD was observed in 40
patients (71.4%). Based on DXA BMD assessment only, 20
patients in the total cohort of 56 patients had osteoporosis
(35.7%); osteopenia was documented in 18 patients (32.1%)
and a low bone mass for age based on Z-scores in two patients
(n = 2/56; 3.6%). Seventeen participants (n = 17/56; 30.4%) had a
T-score of <−2.5 at more than one skeletal site. The DXA lumbar
vertebral fracture assessment (VFA) identified morphometric
vertebral abnormalities in eight patients (14.5%), all≥ 50 years.
Conventional radiology detected significant vertebral com-
pression (> 20% height loss) in 11 (21.2%) patients, including
VFs in three patients in the absence of DXA confirmed osteo-
porosis, thus bringing the total number of participants with
osteoporosis in our cohort to 23 (41.1%).
Osteoporosis was thus diagnosed in this cohort with PHPT
based on BMD measurements in 20 patients and based on ver-
tebral fracture only in an additional 3 patients. All patients with
osteoporosis were either postmenopausal women or men≥ 50
years, with half of this cohort manifesting with osteoporosis
(n = 23/46; 50%). Osteoporosis was documented in 32% (10/
31), 43% (9/21) and 33% (1/3) of mixed-ancestry, white and
black participants. Small numbers limited the ability of this
cohort to report on the contribution of ethnicity to the risk of
osteoporosis in patients with PHPT.
BMD assessment at the different skeletal sites and the presence
of vertebral fractures on conventional radiography for the
cohort that comprised postmenopausal women and men≥ 50
years and for the cohort that included premenopausal women
and men < 50 years are displayed in Table 3.
Table 3: Site-specific bone mineral density and vertebral fracture in menopausal and age cohorts.
Cohort: postmenopausal women and men≥ 50 years (n = 46)
BMD LS (n = 46) FN (n = 39) THR (n = 45) DF (n = 15) Any (n = 46)
• Absolute valuea 0.954 ± 0.203 0.672 ± 0.154 0.813 ± 0.182 0.553 ± 0.129 na
• Mean T-scoreb −1.0 ± 1.7 −1.7 ± 1.4 −1.1 ± 1.5 −2.5 ± 2.2 na
• Osteopenia 14 (30.4%) 15 (38.5%) 13 (28.9%) 2 (13.3%) 18 (39.1%)
• BMD OPc 11 (23.9%) 13 (33.3%) 11 (24.4%) 9 (60%) 20 (43.5%)
Radiography (n = 42)
• VF 11 (%)
• VF and BMD OP 8 (%)
• VF without BMD OP 3 (%)
BMD + radiography
• Osteoporosisd 23 (50%)
Cohort: premenopausal women and men < 50 years (n = 10)
BMD LS (n = 10) FN (n = 9) THR (n = 10) DF (n = 3) Any (n = 10)
• Absolute valuea 0.916 ± 0.99 0.709 ± 0.102 0.824 ± 0.106 0.596 ± 0.129 na
• Mean Z-scoreb −1.1 ± 0.8 −1.0 ± 0.9 −0.8 ± 0.9 −1.3 ± 2.1 na
• Low bone mass 0 (0%) 1 (11.1%) 1 (10.0%) 1 (33.3%) 2 (20%)
• Osteoporosis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Radiography (n = 10)
• VF 0 (0%)
aBMD in g/cm2.
bZ- and T-scores are given as mean ± SD, rest of data expressed as n (%). Definition of osteopenia, low bone mass and osteoporosis as defined in methods section. Radi-
ography for vertebral fracture performed in 52 of the 56 patients.
cBMD OP refers to patients with OP based on BMD measurement in the cohort: postmenopausal women and men≥ 50 years of age with a T-score lower than −2.5SD.
dOsteoporosis refers to patients with BMD OP and/or VF. na = not applicable.
Site-specific BMD as measured by DXA. LS = lumbar spine, FN = femoral neck, THR = total hip region, DF = distal forearm (non-dominant), OP = osteoporosis. ‘Any’ referring
to presence of osteopenia or OP at any site.
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T-scores were calculated only for the cohort that included post-
menopausal women and men≥ 50 years. In this cohort, the
mean T-scores, determined for the different skeletal sites, i.e.
the LS, FN, THR and distal forearm, were −1.0 ± 1.7, −1.7 ± 1.4,
−1.1 ± 1.5 and −2.5 ± 2.2, respectively. The Z-scores were used
diagnostically to determine low bone mass in premenopausal
women and men < 50 years. Z-scores, similar to the T-scores,
were noted to be lowest for the distal forearm in the younger
cohort (–1.3 ± 2.1).
Despite few skeletal surveys beingavailable for scrutiny, five
patients (9.6%) had evidence of osteitis fibrosa cystica: subper-
iosteal erosion was seen in the hands, distal clavicles (Figure 1)
and/or sacro-iliac joints of three patients; ‘salt and pepper skull’
was noted in the CT image of one patient; and a brown tumour
was seen in the hand radiographs of one patient (Figure 2).
Relationship between bone mineral density and
biochemical parameters
The relationship between absolute BMD (g/cm2) and biochemi-
cal parameters was explored, with correction for age and BMI.
BMD was positively associated with 25(OH)D levels only at the
lumbar spine (r = 0.66, p = 0.04). BMD was negatively associated
with (i) ALP in the distal forearm only (r =−0.66, p = 0.04) and (ii)
PTH in the femoral neck only (r =−0.63, p = 0.05). No significant
association was evident between serum calcium level and
absolute BMD at any measured site.
Biochemical parameters within the different BMD subgroups
are presented in Table 4. In the total cohort, a significantly
higher PTH level was seen in those with decreased BMD (osteo-
porosis, osteopenia and low bone mass for age) compared with
those with normal BMD (mean PTH 20.6 vs. 16.7 pmol/l respect-
ively, p = 0.04). No significant differences were evident between
the two groups in terms of calcium, ALP or 25(OH)D levels.
When exploring the same variables in the subgroup of
patients≥ 50 years, PTH levels in the osteoporosis group
tended to be higher compared with both the osteopenia and
normal BMD groups (p = 0.07), reaching statistical significance
only in a direct comparison between those with normal BMD
versus those with osteoporosis (p = 0.02).
There was no association between vertebral fracture (assessed
by VFA or conventional radiology) and PTH or 25(OH)D.
Discussion
In this study, we present a detailed report on the skeletal health
and biochemical characteristics of a cohort of mostly over-
weight patients with symptomatic moderate to severe PHPT,
who underwent surgical parathyroidectomy. More than two-
thirds (71.4%) of the patients had decreased BMD and half
(50%) of the cohort that comprised postmenopausal women
and men≥ 50 years had osteoporosis. One in five patients
had morphometric vertebral fractures at diagnosis.
In the developing world, in contrast to well-resourced health-
care settings, the prevalence of PHPT has not been deter-
mined. Underdiagnosis, underreporting and lack of national
health registries in lesser-resourced countries probably con-
tribute to this. It is therefore not surprising that only three
studies have been published on the nature of PHPT and its
impact on skeletal health in South African patients.23,30,31 In
patients with PHPT in the developed world, the prevalence
of osteoporosis ranges from 24% to 62.9%32,33 and vertebral
fractures from 21% to 47%.33–35 These varied results are
likely due to different study populations, different methods
for diagnosis and change in presentation of the disease over
time. In the current study, the prevalence of osteoporosis
and vertebral fractures in South African patients with PHPT
falls within these ranges.
The reduction in bone density that occurs in PHPT follows a
specific pattern: demineralisation of cortical bone, mainly the
radius, tibia and femur, with relative preservation of trabecular
or cancellous bone (vertebrae, pelvis, ribs).17,36 Concordant with
this, the skeletal site most severely affected in our study was the
distal-third forearm. The mean T-score at this site was lower
compared with the other measured sites (−2.5 ± 2.2) and 60%
(n = 9/15) of measured patients had osteoporosis range BMD.
The proximal femoral region has both cortical and cancellous
bone36 and shows intermediate changes in bone density.37
The total hip site contains more cortical bone compared with
the femoral neck region and it is thus surprising in our cohort
that more bone loss occurred in the femoral neck region
(mean T-score of −1.7 ± 1.4 versus mean T-score of −1.1 ± 1.5
for the total hip region). BMD at the lumbar spine, an area
rich in trabecular bone, was relatively preserved, with a mean
Figure 1: Subperiosteal resorption of the lateral clavicle.
Figure 2: Subperiosteal resorption of medial phalanges and brown
tumour of left third, middle phalanx.
20 Journal of Endocrinology, Metabolism and Diabetes of South Africa 2021; 26(1):16–23
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 31
T-scores were calculated only for the cohort that included post-
menopausal women and men≥ 50 years. In this cohort, the
mean T-scores, determined for the different skeletal sites, i.e.
the LS, FN, THR and distal forearm, were −1.0 ± 1.7, −1.7 ± 1.4,
−1.1 ± 1.5 and −2.5 ± 2.2, respectively. The Z-scores were used
diagnostically to determine low bone mass in premenopausal
women and men < 50 years. Z-scores, similar to the T-scores,
were noted to be lowest for the distal forearm in the younger
cohort (–1.3 ± 2.1).
Despite few skeletal surveys beingavailable for scrutiny, five
patients (9.6%) had evidence of osteitis fibrosa cystica: subper-
iosteal erosion was seen in the hands, distal clavicles (Figure 1)
and/or sacro-iliac joints of three patients; ‘salt and pepper skull’
was noted in the CT image of one patient; and a brown tumour
was seen in the hand radiographs of one patient (Figure 2).
Relationship between bone mineral density and
biochemical parameters
The relationship between absolute BMD (g/cm2) and biochemi-
cal parameters was explored, with correction for age and BMI.
BMD was positively associated with 25(OH)D levels only at the
lumbar spine (r = 0.66, p = 0.04). BMD was negatively associated
with (i) ALP in the distal forearm only (r =−0.66, p = 0.04) and (ii)
PTH in the femoral neck only (r =−0.63, p = 0.05). No significant
association was evident between serum calcium level and
absolute BMD at any measured site.
Biochemical parameters within the different BMD subgroups
are presented in Table 4. In the total cohort, a significantly
higher PTH level was seen in those with decreased BMD (osteo-
porosis, osteopenia and low bone mass for age) compared with
those with normal BMD (mean PTH 20.6 vs. 16.7 pmol/l respect-
ively, p = 0.04). No significant differences were evident between
the two groups in terms of calcium, ALP or 25(OH)D levels.
When exploring the same variables in the subgroup of
patients≥ 50 years, PTH levels in the osteoporosis group
tended to be higher compared with both the osteopenia and
normal BMD groups (p = 0.07), reaching statistical significance
only in a direct comparison between those with normal BMD
versus those with osteoporosis (p = 0.02).
There was no association between vertebral fracture (assessed
by VFA or conventional radiology) and PTH or 25(OH)D.
Discussion
In this study, we present a detailed report on the skeletal health
and biochemical characteristics of a cohort of mostly over-
weight patients with symptomatic moderate to severe PHPT,
who underwent surgical parathyroidectomy. More than two-
thirds (71.4%) of the patients had decreased BMD and half
(50%) of the cohort that comprised postmenopausal women
and men≥ 50 years had osteoporosis. One in five patients
had morphometric vertebral fractures at diagnosis.
In the developing world, in contrast to well-resourced health-
care settings, the prevalence of PHPT has not been deter-
mined. Underdiagnosis, underreporting and lack of national
health registries in lesser-resourced countries probably con-
tribute to this. It is therefore not surprising that only three
studies have been published on the nature of PHPT and its
impact on skeletal health in South African patients.23,30,31 In
patients with PHPT in the developed world, the prevalence
of osteoporosis ranges from 24% to 62.9%32,33 and vertebral
fractures from 21% to 47%.33–35 These varied results are
likely due to different study populations, different methods
for diagnosis and change in presentation of the disease over
time. In the current study, the prevalence of osteoporosis
and vertebral fractures in South African patients with PHPT
falls within these ranges.
The reduction in bone density that occurs in PHPT follows a
specific pattern: demineralisation of cortical bone, mainly the
radius, tibia and femur, with relative preservation of trabecular
or cancellous bone (vertebrae, pelvis, ribs).17,36 Concordant with
this, the skeletal site most severely affected in our study was the
distal-third forearm. The mean T-score at this site was lower
compared with the other measured sites (−2.5 ± 2.2) and 60%
(n = 9/15) of measured patients had osteoporosis range BMD.
The proximal femoral region has both cortical and cancellous
bone36 and shows intermediate changes in bone density.37
The total hip site contains more cortical bone compared with
the femoral neck region and it is thus surprising in our cohort
that more bone loss occurred in the femoral neck region
(mean T-score of −1.7 ± 1.4 versus mean T-score of −1.1 ± 1.5
for the total hip region). BMD at the lumbar spine, an area
rich in trabecular bone, was relatively preserved, with a mean
Figure 1: Subperiosteal resorption of the lateral clavicle.
Figure 2: Subperiosteal resorption of medial phalanges and brown
tumour of left third, middle phalanx.
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T-score near normal (−1.0 ± 1.7). Interpretation of lumbar spine
BMD, especially in older people, must be done cautiously.
Falsely elevated BMD in the lumbar spine can occur with
osteoarthritic spondylosis, acquired scoliosis, vertebral fractures
and aortic calcifications.38–40 Given the age and extent of hyper-
calcemia in our patients, extra-skeletal calcifications may also
have accounted for a falsely elevated lumbar spine BMD. In all
three last-mentioned sites the percentage of patients with
osteoporosis range BMD was, however, similar (LS 23.9%; FN
33.3% and TH 24.4%).
Despite the apparent preserved axial BMD, epidemiological
studies describing fracture risk in PHPT report similar fracture
risk in both vertebral and non-vertebral sites.15 VFs are known
to occur more commonly in PHPT than matched controls19,20
and these fractures appear to occur at a higher BMD than in
patients without PHPT,33,34 suggesting that factors other than
reduced BMD play a role.
PHPT represents a state of high bone resorption with increased
bone turnover, a well-documented BMD-independent risk
factor for decreased bone quality and fragility.41 An association
between the degree of PTH elevation and the severity of skeletal
involvement has previously been reported42 and was reaffirmed
in our study. The mean PTH level was significantly higher in the
patients with decreased BMD when compared with those who
had normal BMD in the total cohort (mean PTH 16.7 vs.
20.6 pmol/l respectively, p = 0.04). A significantly higher mean
PTHwas also noted in a direct comparison of patientswith osteo-
porosis and those with normal BMD (mean PTH 36.2 vs
16.7 pmol/l, p = 0.02). An elevated ALP level was noted in 21 of
45 patients tested (46.7%), indicative of decreased skeletal min-
eralisation. Thismay be a consequence of accelerated bone turn-
over in PHPT and may impact negatively on bone strength and
bone quality irrespective of BMD. A significant correlation
between ALP and PHPT bone disease could be expected,4 but
was not proven to be significant in this study. Research using
high-resolution peripheral quantitative computed tomography
(HRpQCT) has confirmed microarchitectural deterioration and
decreased volumetric density at both cortical and trabecular
sites,43,44 findings in keeping with a high bone turnover state
with a consequent adverse impact on bone quality.
No significant differences in serum calcium or 25(OH)D were
found between patients with normal and decreased BMD. The
impact of vitamin D deficiency on skeletal health in PHPT
remains to be fully defined. First, it appears that vitamin D
deficiency is more common in patients with PHPT than in
matched controls45,46 and, second, that vitamin D deficient
patients with PHPT have more severe skeletal manifestations
of the disease.11,47 What is unclear, however, is the causality
of the relationship:48 does pre-existing vitamin D deficiency
worsen the clinical picture of PHPT, or does PHPT cause
vitamin D deficiency, particularly if severe? There is ongoing
active research in this area. Vitamin D deficiency is common
in South Africa; deficient levels have been found in 38% to
55%49,50 of patients. In our study, deficiency was seen in 39
patients (79.6%) with PHPT, exceeding the deficiency rates
seen in other South African cohorts and supporting the evi-
dence that vitamin D deficiency is more common in PHPT.
While we were able to show an inverse correlation between
25(OH)D and PTH (r =−0.43, p < 0.01), this did not translate to
a significant relationship with osteoporosis, a finding that has
been reported in other studies.51 It is noteworthy that normal
25(OH)D was only documented in 2 of the 49 patients who
underwent testing and the almost universal lowered 25(OH)D
levels in the study cohort may be the reason why a significant
correlation with adverse BMD outcome was not demonstrated.
The true existence of a correlation between 25(OH)D deficiency
and severity of bone disease in PHPT has not been consistently
forthcoming in the literature to date; some studies have found a
significant relationship,42 while others, like ours, have not.52
The once common and pathognomonic mode of presentation
of PHPT, osteitis fibrosa cystica, is considered a rarity in high-
income nations today.1,6,53 Developing countries such as
Brazil, India and Thailand, however, still report rates of OFC
between 6.7% and 47%.10 In South Africa, a 1976 study30
reported three cases of PHPT with gross bone disease, which
the authors ascribed to a severe variant as opposed to
delayed presentation and management. Paruk et al. reported
a 47.6% (n = 10/21) prevalence of hyperparathyroidism-related
bone disease on plain radiographs (a combined value given
for subperiosteal resorption, bone cysts, loss of skull lamina
dura, bone sclerosis and brown tumours).23 Despite very few
Table 4: Biochemical parameters within BMD subgroups.
Total cohort (n = 56)
Total cohort Normal BMD Decreased BMD p-value*
Calcium (mmol/l) 2.93 (2.81, 3.19) 2.93 (2.84, 3.12) 2.95 (2.81, 3.27) 0.74
Phosphate (mmol/l) 0.87 (0.71, 1.00) 0.80 (0.67, 0.94) 0.89 (0.73, 1.02) 0.40
PTH (pmol/l) 19.40 (14.65, 42.0) 16.7 (14.1, 20.8) 20.6 (16.0, 52.6) 0.04*
ALP (U/l) 88.0 (75.0, 122.0) 82.0 (73.0, 106.0) 89.0 (77.0, 133.5) 0.28
25(OH)D (nmol/l) 34.0 (24.30, 47.2) 32.0 (21.0, 51.8) 35.90 (28.6, 47.0) 0.54
Cohort: postmenopausal women and men≥ 50 years (n = 46)
Normal BMD Osteopenia Osteoporosis p-value**
Calcium (mmol/l) 2.91 (2.79, 3.02) 2.91 (2.80, 3.17) 3.05 (2.81, 3.42) 0.42
Phosphate (mmol/l) 0.91 (0.74, 1.05) 0.94 (0.80, 1.03) 0.89 (0.71, 1.00) 0.65
PTH (pmol/l) 16.1 (11.9, 19.5) 18.7 (13.7, 45.7) 36.4 (17.3, 80.4) 0.07***
ALP (U/l) 105.5 (82.0, 119.0) 79.0 (69.0, 90.0) 108.0 (85.0, 151.0) 0.13
25(OH)D (nmol/l) 33.7 (26.5, 53.3) 39.0 (29.7, 55.9) 31.1 (19.4, 42.8) 0.18
*p-value comparing normal BMD with decreased BMD.
**p-value comparing the three categories of normal, osteopenia and osteoporosis in postmenopausal women and men ≥ 50 years.
***In a direct comparison of PTH in normal BMD vs. osteoporosis p = 0.02.
Values given are median (IQR). Decreased BMD referring to either low bone mass in patients < 50 years and osteopenia or osteoporosis in patients ≥ 50 years.
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dedicated skeletal surveys in our study, OFC was seen in five
patients (9.6%). These were likely patients who were suspected
of having more severe PHPT or were symptomatic from skeletal
disease. This figure may well have been higher had all patients
undergone screening radiographs.
Limitations of this study include its retrospective nature and
small sample size; it does, however, represent the largest
study to date of bone health in South African patients with
PHPT. By selecting a cohort of patients with PHPT requiring
surgery, bias towards more severe PHPT is introduced and
may overestimate the severity of skeletal disease in a broader
PHPT population. Of a total of 104 patients who underwent
parathyroidectomy for PHPT, only 56 (53.8%) had a DXA study
on record, highlighting deficient evaluation of skeletal health
in many patients with PHPT. Studies have shown that, even in
asymptomatic patients, VFs and osteoporosis will be detected
in 34.7% and 65.8% of cases if radiographic imaging and DXA
is performed.33
Conclusion
In the South African public sector, the majority of patients diag-
nosed with PHPT have skeletal disease. Insufficient vitamin D is
almost universal. This emphasises the importance of skeletal
and biochemical assessment and calls for a multidisciplinary
approach to managing patients with PHPT.
Disclosure statement – No potential conflict of interest was









1. Zanocco KA, Yeh MW. Primary hyperparathyroidism. Endocrinol
Metab Clin North Am. 2017 Mar;46(1):87–104. https://doi.org/10.
1016/j.ecl.2016.09.012
2. Shepard MM, Smith JW. Hypercalcemia. Am J Med Sci. 2007 Nov;334
(5):381–385. https://doi.org/10.1097/MAJ.0b013e31812f4947
3. Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, Seldin
D, et al. Skeletal disease in primary hyperparathyroidism. J Bone
Miner Res. 1989;4(3):283–291. https://doi.org/10.1002/jbmr.
5650040302
4. Mosekilde L. Primary hyperparathyroidism and the skeleton. Clin
Endocrinol (Oxf). 2008 Jul;69(1):1–19. https://doi.org/10.1111/j.
1365-2265.2007.03162.x
5. Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R,
Marcocci C, et al. Guidelines for the management of asymptomatic
primary hyperparathyroidism: summary statement from the fourth
international workshop. J Clin Endocrinol Metab. 2014 Oct;99
(10):3561–3569. https://doi.org/10.1210/jc.2014-1413
6. Makras P, Anastasilakis AD. Bone disease in primary hyperparathyr-
oidism. Metab Clin Exp. 2018 Mar;80:57–65. https://doi.org/10.1016/
j.metabol.2017.10.003
7. Bandeira F, Cassibba S. Hyperparathyroidism and bone health. Curr
Rheumatol Rep. 2015 Jul 24;17(7):48. https://doi.org/10.1007/
s11926-015-0523-2
8. Mundy G, Cove D, Fisken R. Primary hyperparathyroidism: changes
in the pattern of clinical presentation. Lancet. 1980 Jun;315
(8182):1317–1320. https://doi.org/10.1016/S0140-6736(80)91783-3
9. Heath H, Hodgson SF, Kennedy MA. Primary hyperparathyroidism. N
Engl J Med. 1980 Jan 24;302(4):189–193. https://doi.org/10.1056/
NEJM198001243020402
10. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano
NE, et al. Current issues in the presentation of asymptomatic
primary hyperparathyroidism: proceedings of the fourth inter-
national workshop. J Clin Endocrinol Metab. 2014 Oct;99(10):3580–
3594. https://doi.org/10.1210/jc.2014-1415
11. Bilezikian JP, Meng X, Shi Y, Silverberg SJ. Primary hyperparathyroid-
ism in women: a tale of two cities–New York and Beijing. Int J Fertil
Womens Med. 2000;45(2):158–165.
12. Bandeira F, Correia A. Clinical presentation of primary hyperpar-
athyroidism. In: The Parathyroids. Elsevier; 2015. p. 309–15. https://
doi.org/10.1016/B978-0-12-397166-1.00020-5
13. Bilezikian JP, Silverberg SJ, Shane E, Parisien M, Dempster DW.
Characterization and evaluation of asymptomatic primary hyperpar-
athyroidism. J Bone Miner Res. 2009 Dec 3;6(S2):S85–S89. https://
doi.org/10.1002/jbmr.5650061419
14. Adami S, Braga V, Squaranti R, Rossini M, Gatti D, Zamberlan N. Bone
measurements in asymptomatic primary hyperparathyroidism.
Bone. 1998 May;22(5):565–570. https://doi.org/10.1016/S8756-3282
(98)00042-8
15. Khosla S, Melton J. Fracture risk in primary hyperparathyroidism. J
Bone Miner Res. 2002 Nov;17(Suppl 2):N103–N107.
16. Yu N, Donnan PT, Flynn RW, Murphy JM, Smith D, Rudman A, et al.
Increased mortality and morbidity in mild primary hyperparathyroid
patients. Clin Endocrinol. 2010 Jul;73(1):30–34. https://doi.org/10.
1111/j.1365-2265.2009.03766.x
17. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, et al.
The natural history of primary hyperparathyroidism with or without
parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008
Sep;93(9):3462–3470. https://doi.org/10.1210/jc.2007-1215
18. Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Amy Liu I-L, Harari A,
et al. Incidence and prevalence of primary hyperparathyroidism in
a racially mixed population. J Clin Endocrinol Metab. 2013 Mar
1;98(3):1122–1129. https://doi.org/10.1210/jc.2012-4022
19. Kenny A, Macgillivray D, Pilbeam C, Crombie H, Raisz L. Fracture inci-
dence in postmenopausal women with primary hyperparathyroid-
ism. Surgery. 1995 Jul;118(1):109–114. https://doi.org/10.1016/
S0039-6060(05)80017-0
20. Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E,
et al. Morphometric vertebral fractures in postmenopausal women
with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009
Jul;94(7):2306–2312. https://doi.org/10.1210/jc.2008-2006
21. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year pro-
spective study of primary hyperparathyroidism with or without
parathyroid surgery. N Engl J Med. 1999 Oct 21;341(17):1249–
1255. https://doi.org/10.1056/NEJM199910213411701
22. Vestergaard P. Cohort study of risk of fracture before and after
surgery for primary hyperparathyroidism. Br Med J. 2000 Sep
9;321(7261):598–602. https://doi.org/10.1136/bmj.321.7261.598
23. Paruk IM, Esterhuizen TM, Maharaj S, Pirie FJ, Motala AA.
Characteristics, management and outcome of primary hyperpar-
athyroidism in South Africa: a single-centre experience. Postgrad
Med J. 2013 Nov;89(1057):626–631. https://doi.org/10.1136/
postgradmedj-2012-131707
24. Yeh MW, Zhou H, Adams AL, Ituarte PHG, Li N, Liu I-LA, et al. The
relationship of parathyroidectomy and bisphosphonates with frac-
ture risk in primary hyperparathyroidism. Ann Intern Med. 2016
Jun 7;164(11):715. https://doi.org/10.7326/M15-1232
25. World Health Organization (WHO) [Cited 2020 Jan 22] Available
from: https://apps.who.int/bmi/index.jsp
26. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,
Heaney RP, et al. Evaluation, treatment, and prevention of vitamin
D deficiency: an endocrine society clinical practice guideline. J Clin
Endocrinol Metab. 2011 Jul;96(7):1911–1930. https://doi.org/10.
1210/jc.2011-0385
27. Alexeeva L, Burkhardt P, Christiansen C, Cooper C, Delmas P, Johnell
O, et al. Reviews and notes: assessment of fracture risk and its appli-
cation to screening for postmenopausal osteoporosis. Ann Intern
Med. 1995 Apr 1;122(7):558. https://doi.org/10.7326/0003-4819-
122-7-199504010-00024
22 Journal of Endocrinology, Metabolism and Diabetes of South Africa 2021; 26(1):16–23
The page number in the footer is not for bibliographic referencingwww.tandfonline.com/oemd 33
dedicated skeletal surveys in our study, OFC was seen in five
patients (9.6%). These were likely patients who were suspected
of having more severe PHPT or were symptomatic from skeletal
disease. This figure may well have been higher had all patients
undergone screening radiographs.
Limitations of this study include its retrospective nature and
small sample size; it does, however, represent the largest
study to date of bone health in South African patients with
PHPT. By selecting a cohort of patients with PHPT requiring
surgery, bias towards more severe PHPT is introduced and
may overestimate the severity of skeletal disease in a broader
PHPT population. Of a total of 104 patients who underwent
parathyroidectomy for PHPT, only 56 (53.8%) had a DXA study
on record, highlighting deficient evaluation of skeletal health
in many patients with PHPT. Studies have shown that, even in
asymptomatic patients, VFs and osteoporosis will be detected
in 34.7% and 65.8% of cases if radiographic imaging and DXA
is performed.33
Conclusion
In the South African public sector, the majority of patients diag-
nosed with PHPT have skeletal disease. Insufficient vitamin D is
almost universal. This emphasises the importance of skeletal
and biochemical assessment and calls for a multidisciplinary
approach to managing patients with PHPT.
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